Core Points - Ironman International Ltd. has granted a total of 5,155,000 stock options to directors, officers, employees, and consultants, each exercisable at $0.10 for three years, with immediate vesting [1] - The company has issued 1,100,000 restricted share units (RSUs) to a consultant, which will vest one year from the grant date [2] - The acquisition of 1097195 B.C. Ltd. and Ironman Directional Drilling US Inc. is seen as a significant step in strengthening the operational platform and advancing growth strategy [3][4] - The CEO emphasizes the unique competitive advantage provided by the combination of a scalable public company platform and over 25 years of private-sector operational expertise [5] - The company aims for relentless execution, bold innovation, disciplined expansion, and a focus on building enduring shareholder value [7] - The CFO highlights that the acquisition strengthens the capital base, expands market reach, and positions the company for sustainable long-term growth [8] Company Strategy - The acquisition is described as a decisive turning point for the company, marking a refreshed vision and a motivated leadership team [4][5] - The company is committed to transparent disclosure, strong governance standards, and protecting shareholder interests [8] - The leadership team is characterized by determination, creativity, accountability, and pride in their work, which differentiates the company in the industry [6] Future Outlook - The company expresses confidence in its ability to adapt quickly to market shifts, regulatory changes, and major project opportunities [5] - The leadership team is focused on executing the growth strategy and enhancing shareholder value [7]

Group 1 - Gold X2 Mining Inc. has filed its third quarter interim financial statements and Management's Discussion and Analysis, available on SEDAR+ [1] - Gold X2 is focused on acquiring and advancing primary gold assets in tier-one jurisdictions, led by experienced management and backed by a prominent private equity firm [2] - The company has invested over $75 million in the Moss Gold Project, completing approximately 100,000 meters of drilling, contributing to a total of over 255,000 meters drilled [2] Group 2 - The updated NI 43-101 mineral resource estimate for the Moss Gold Project shows 1.54 million ounces of Indicated gold resources at 1.23 g/t Au and 5.20 million ounces of Inferred gold resources at 1.11 g/t Au [2] - The mineral resource estimate covers only 3.6 kilometers of a 35+ kilometer mineralized trend, indicating significant potential for further development [2] - The Moss Gold Project is one of the few remaining major Canadian gold deposits positioned for development in the current cycle [2]

Core Insights - Ecopetrol has successfully negotiated the potential acquisition of seven companies from Grenergy Renovables S.A. in Colombia, which are involved in solar photovoltaic projects with a total estimated renewable energy generation capacity of approximately 12.6 MWp per project [1][2]. Group 1: Acquisition Details - The acquisition involves companies located in the departments of Córdoba (3), Cesar (2), Magdalena (1), and Sucre (1) [1]. - The transaction is subject to certain conditions precedent and legal requirements before finalization [2][4]. Group 2: Strategic Goals - Upon completion, the acquisition will help Ecopetrol advance its decarbonization and energy transition goals, contributing to its target of 900 MW of self-generated renewable energy [3]. - These initiatives are aligned with Ecopetrol's 2040 Strategy, "Energy that Transforms," and aim to enhance the company's energy matrix while supporting low-emission energy generation for self-consumption [3]. Group 3: Company Overview - Ecopetrol is the largest company in Colombia and a major integrated energy player in the Americas, responsible for over 60% of the country's hydrocarbon production [5]. - The company has significant operations in energy transmission, drilling, and exploration across various countries in the Americas, including the United States, Brazil, and Mexico [5].

At 94, Jaiprakash Gaur should have been sitting atop the hill of Indian enterprise, having built a multi-billion-dollar conglomerate from scratch. Instead, he now watches his empire in ruins, his reputation in tatters. The man once celebrated as a builder could only stand by as the National Company Law Tribunal (NCLT) admitted his flagship, Jaiprakash Associates Ltd, into insolvency. Weighed down by his group’s staggering ₹57,000 crore debt, accumulated over decades of ambition that produced expressways, d ...

Core Insights - Maase Inc. has appointed Mr. Jingkai Li as the new chairman of the board, succeeding Ms. Hong Suong Nguyen, effective November 28, 2025 [1][2][3] Company Overview - Maase Inc. was founded in 2010 and has evolved from being known as Highest Performances Holdings Inc. and Puyi Inc. to a provider of intelligent technology-driven family and enterprise services [4] - The company's mission focuses on enhancing the quality of life for families globally through technological intelligence and capital investments, targeting high-quality enterprises with global potential [4] Leadership Background - Mr. Jingkai Li holds an executive master's degree in business administration from Macau University of Science and Technology and has over a decade of experience in the green industry [2] - He previously led Guangxi Qinyuan Environmental Protection Co., Ltd., where he built a technology-driven environmental protection industrial group, gaining expertise in operational management and industrial integration [2] - Mr. Li's experience includes strategic investments in new energy and smart technology sectors, positioning him as an ideal leader for Maase's growth [2] Strategic Vision - Mr. Li expressed his commitment to leveraging his experience in the green industry and strategic investment to foster innovation across Maase's business units [3] - The company has shown significant potential in areas such as smart car wash, energy storage batteries, and wellness businesses, which Mr. Li aims to capitalize on [3]

Core Viewpoint - Rapid Dose Therapeutics Corp. intends to extend the maturity date of its outstanding secured convertible notes from November 30, 2025, to November 30, 2026, as part of a strategic financial maneuver to manage its debt obligations [1]. Financing Details - The financing involved an offering of units priced at $1.00 per unit, each consisting of $1.00 principal amount of notes convertible at $0.17 per share, along with five common share purchase warrants with an exercise price between $0.14 and $0.17 per share, expiring on November 30, 2025. The total principal amount of notes issued was $3,134,445, along with 15,672,225 warrants [2]. Extension Agreement - Noteholders holding $3,084,445 of notes have agreed to extend the maturity date and the expiry date of their accompanying warrants to November 30, 2026, with an adjusted exercise price of $0.16. An extension fee of 5% will be paid in common shares at a price of $0.16 per share. One noteholder with a $50,000 note will receive cash repayment instead of an extension [3]. Interest Rate Adjustment - The interest rate on the notes will increase from 12% to 18% per annum, calculated and compounded monthly, with interest payable quarterly in arrears in common shares based on the closing market price on the Canadian Securities Exchange [4]. Accrued Interest Payment - The company plans to issue common shares to satisfy accrued and unpaid interest totaling $62,860.65 on the notes, due on the initial maturity date of November 30, 2025. This issuance is expected to occur no later than December 15, 2025 [5]. Securities Hold Period - All securities issued under the extension and for the payment of accrued interest will be subject to a hold period of four months and one day from the date of issuance [6]. Insider Participation - Certain insiders hold a total of $1,696,371 of notes and participated in the extension. The company is relying on exemptions from valuation and minority shareholder approval requirements due to the nature of the transaction being within the related party context [7]. Company Overview - Rapid Dose Therapeutics is a Canadian biotechnology company focused on innovative drug delivery solutions, with its flagship product QuickStrip™, an orally dissolvable film that can deliver various active ingredients rapidly into the bloodstream [8].

Core Viewpoint - Rakovina Therapeutics Inc. has announced the extension of the maturity date for its 12.0% convertible debentures from November 29, 2025, to January 28, 2026, following consent from debentureholders representing at least 66 2/3% of the outstanding principal [1][2] Group 1: Convertible Debentures - The total principal amount of the convertible debentures is $1,454,000.00, and the interest rate will remain at 12.0% during the extension period [1][2] - The extension is subject to approval from the TSX Venture Exchange [2] Group 2: Related Party Disclosure - Certain directors of the company own approximately $100,000 principal amount of the convertible debentures, representing about 6.9% of the outstanding principal [3] - The participation of these directors in the extension is classified as a "related party transaction" under applicable regulations, and the company has relied on exemptions from formal valuation and minority shareholder approval requirements [3] Group 3: Warrant Incentive Program - The company's early exercise warrant incentive program expired on September 2, 2025, with no warrants being exercised [4] Group 4: Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered technologies for targeting DNA-damage response [5][6] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [6]

Core Viewpoint - Rakovina Therapeutics Inc. has announced the extension of the maturity date for its 12.0% convertible debentures from November 29, 2025, to January 28, 2026, following consent from debentureholders representing at least 66 2/3% of the outstanding principal [1][2] Group 1: Convertible Debentures - The total principal amount of the convertible debentures is $1,454,000.00, and the interest rate will remain at 12.0% during the extension period [1][2] - The extension is subject to approval from the TSX Venture Exchange [2] Group 2: Related Party Disclosure - Certain directors of the company own approximately $100,000 principal amount of the convertible debentures, representing about 6.9% of the outstanding principal [3] - The participation of these directors in the extension is classified as a "related party transaction" under applicable regulations, and the company has relied on exemptions from formal valuation and minority shareholder approval requirements [3] Group 3: Warrant Incentive Program - The early exercise warrant incentive program expired on September 2, 2025, with no warrants being exercised [4] Group 4: Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered technologies for targeting DNA-damage response [5][6] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [6]

The athleisure brand's estranged founder, Chip Wilson, is telling anyone who will listen how the current leadership is messing up. ...

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2025) - Blue Star Gold Corp. (TSXV: BAU) (OTCQB: BAUFF) (FSE: 5WP0) ("Blue Star" or the "Company") announces that, further to its news releases of October 30, 2025 and November 4, 2025, it has closed the final tranche of its non-brokered private placement raising proceeds of $100,000 through the issuance of 400,000 flow-through common shares (each, a "FT Share") at $0.25 per FT Share (the "Private Placement"). The Company raised total proceeds of ...